A Major Breakthrough of Traditional Chinese Medicine for Treatment of Sequelae of Guillain-Barre Syndrome
Specialty department of muscle atrophy of Yiling Hospital affiliated to Hebei Medical University has borne the project of "Experiment and Clinical Research of Traditional Chinese Medicine Zhouluotong Capsule in the Treatment of Sequelae of Guillain - Barre Syndrome. Through the scientific research appraisal of experts of key research medical institutions in China from Peking Union Medical College Hospital, China Academy of Traditional Chinese Medicine Hospital, Nanjing University of Traditional Chinese Medicine etc. it has reached the domestic advanced level.
Guillain - Barre syndrome, also known as acute infectious polyneuritis, is characterized by symmetric progressive flaccid paralysis of limbs, decrease or disappearance of tendinous reflex, or accompanied with peripheral sensory disturbance as the clinical features. About 1/3 patients can be left over with sequlae. 10% of patients may have severe limb dysfunction. It is one of the important causes leading to paralysis. Vice President Professor Chen Jinlian of Yiling Hospital affiliated to Hebei Medical University has started the research of traditional Chinese medicine for the treatment of the sequelae of Guillain – Barre syndrome since the nineties of the last century sequelae of research and he has researched and developed Zhouluotong Capsule. The clinical applications have been for more than ten years, achieving satisfactory curative effect.
To further verify the efficacy and to explore its mechanism of action, they have carried out related experiments of Zhouluotong. Results show that Zhouluotong Capsule has protective effect on peripheral neuropathy on rats, which can reduce the incidence of neuropathy, exert a protective effect on the atrophy of nerve fibers and enhance muscle strength and endurance. In addition, Zhouluotong capsule also has anti-inflammatory effect, which can effectively promote the recovery of limb function in patients with paralysis.
没有评论:
发表评论